

Lobar Resin Y90 for mCRC #1

Dr. Zachary T. Berman

Associate Clinical Professor of Radiology University of California, San Diego San Diego, CA

This presentation reflects Dr. Berman's clinical experience with the TriNav[®] Infusion System. Dr. Berman is a consultant for TriSalus[™] Life Sciences and has been compensated for this content. Results are not predictive of outcomes in other cases.




© 2024 TriSalus[™] Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution. MKT-0521 V1.0

Case Description


- 54-year-old male with aggressive, bi-lobar, metastatic colorectal cancer
- Liver-only disease
- Progressing on a combination of first- and second-line chemotherapy
- After mapping with a traditional microcatheter, treated both lobes with resin Y90 delivered with TriNav
- Selected TriNav for radioembolization due to the hypovascular nature of the tumors

Pre-Treatment CT

Bi-lobar, hypovascular, mCRC throughout the liver



Initial Angiogram using a Traditional Microcatheter




At the time of mapping with a traditional microcatheter, hypervascularity of the tumors is not visible

© 2024 TriSalus™ Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution.


Left Lobe Angiography using TriNav at Treatment Procedure

Same injection settings and same catheter tip placement

Traditional Microcatheter




TriNav



Tumors enhancing on angiography using TriNav

Cone Beam CT


Traditional Microcatheter MAA Mapping Procedure TriNav Radioembolization Procedure



Better tumor enhancement seen in both lobes when TriNav is used to deliver the radioembolization

© 2024 TriSalus™ Life Sciences. All Rights Reserved. Strictly Confidential. Not for Distribution.

CEA – Tumor Marker



The peak CEA tumor marker is at the time of Y90 TARE.

Following treatment, the CEA went to zero with continuation of same-line chemotherapy



Indications For Use

The TriNav[®] and TriNav[®] LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.^{1,2}

Contraindications

The TriNav[®] and TriNav[®] LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).^{1,2}

Rx Only For the safe and proper use of TriNav[®] and TriNav[®] LV, refer to their individual Instructions for Use.

This content is sponsored by TriSalus Life Sciences[®]. Results are not predictive of outcomes in other cases.

1.TriSalus™ TriNav® Infusion System, Instructions for Use 2.TriSalus™ TriNav® LV Infusion System, Instructions for Use

